Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

Overview of attention for article published in Lancet Infectious Diseases, March 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

news: 2 news outlets

twitter: 12 X users

Citations

dimensions_citation: 106 Dimensions

Readers on

mendeley: 148 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

DSM265: Neues Malariamittel besteht erste Tests zur Therapie... (30.03.2017)

Deutsches Ärzteblatt, 30 Mar 2017

Medizin Donnerstag, 30. Mrz 2017 Genf und Tbingen Der Wirkstoff DSM265, der ein fr Malariaparasiten essenzielles…

Studies show single-dose potential for new malaria drug

Centre for Disease Research and Policy, 29 Mar 2017

Two human challenge studies on a new malaria drug called DSM265 yielded promising data about safety and dosage and how the drug…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.